Related Experiment Videos
Long-term tolerability of lamotrigine: data from a 6-year continuation study
Edward Faught1, Fumisuke U Matsuo, Steven Schachter
1Department of Neurology, University of Alabama at Birmingham Epilepsy Center, Civitan International Research Center 312, 1719 6th Avenue South, Birmingham, AL 35294, USA. faught@uab.edu
Epilepsy & Behavior : E&B
|January 31, 2004
Summary
Long-term use of lamotrigine as monotherapy or adjunctive therapy for epilepsy demonstrated sustained efficacy and tolerability in adult patients. Adverse events were generally mild and led to few discontinuations over six years.
Area of Science:
- Neurology
- Clinical Pharmacology
- Epilepsy Research
Background:
- Epilepsy affects millions worldwide, necessitating long-term treatment strategies.
- Lamotrigine is an established antiepileptic drug used for partial seizures.
- Assessing long-term outcomes of antiepileptic drug therapy is crucial for patient management.
Purpose of the Study:
- To evaluate the long-term tolerability and efficacy of lamotrigine.
- To assess lamotrigine's safety profile as monotherapy and adjunctive therapy.
- To determine the impact of lamotrigine on overall clinical status in adult epilepsy patients over six years.
Main Methods:
- An open-label, 6-year continuation study involving 527 adult patients with epilepsy.
- Patients received lamotrigine as monotherapy or adjunctive therapy.
- Regular study visits every 24 weeks monitored tolerability, efficacy, and adverse events.
Main Results:
- 36% of patients showed moderate to marked improvement in clinical status.
- The most common adverse events were dizziness, diplopia, and headache.
- Only 2.7% experienced serious adverse events (accidental injury); discontinuation due to adverse events was low (28 patients).
Conclusions:
- Lamotrigine, used long-term as monotherapy or adjunctive therapy, is well-tolerated in adult epilepsy patients.
- The drug shows sustained efficacy and a favorable safety profile over a 6-year period.
- Adverse events are generally manageable and rarely lead to treatment discontinuation.